Abstract
Radiolabeled antagonists of specific peptide receptors identify a higher number of receptor binding sites than agonists and may thus be preferable for in vivo tumor targeting. In this study, two novel radioiodinated 1,4-benzodiazepines, (S)-1-(3-iodophenyl)-3-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea (9) and (R)-1-(3-iodophenyl)-3-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea (7), were developed. They were characterized in vitro as high affinity selective antagonists at cholecystokinin types 1 and 2 (CCK(1) and CCK(2)) receptors using receptor binding, calcium mobilization, and internalization studies. Their binding to human tumor tissues was assessed with in vitro receptor autoradiography and compared with an established peptidic CCK agonist radioligand. The (125)I-labeled CCK(1) receptor-selective compound 9 often revealed a substantially higher amount of CCK(1) receptor binding sites in tumors than the agonist (125)I-CCK. Conversely, the radioiodinated CCK(2) receptor-selective compound 7 showed generally weaker tumor binding than (125)I-CCK. In conclusion, compound 9 is an excellent radioiodinated nonpeptidic antagonist ligand for direct and selective labeling of CCK(1) receptors in vitro. Moreover, it represents a suitable candidate to test antagonist binding to CCK(1) receptor-expressing tumors in vivo.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Autoradiography
-
Benzodiazepines / chemical synthesis*
-
Benzodiazepines / chemistry
-
Benzodiazepines / pharmacology
-
Binding Sites
-
CHO Cells
-
Calcium / metabolism
-
Cricetinae
-
Cricetulus
-
Gallbladder / diagnostic imaging
-
Gallbladder / metabolism
-
Gastrointestinal Stromal Tumors / diagnostic imaging
-
Gastrointestinal Stromal Tumors / metabolism
-
Humans
-
Iodine Radioisotopes
-
Leiomyoma / diagnostic imaging
-
Leiomyoma / metabolism
-
Ligands
-
Meningioma / diagnostic imaging
-
Meningioma / metabolism
-
Phenylurea Compounds / chemical synthesis*
-
Phenylurea Compounds / chemistry
-
Phenylurea Compounds / pharmacology
-
Radioligand Assay
-
Radionuclide Imaging
-
Radiopharmaceuticals / chemical synthesis*
-
Radiopharmaceuticals / chemistry
-
Radiopharmaceuticals / pharmacology
-
Receptor, Cholecystokinin A / antagonists & inhibitors*
-
Receptor, Cholecystokinin A / metabolism
-
Receptor, Cholecystokinin B / antagonists & inhibitors*
-
Receptor, Cholecystokinin B / metabolism
-
Stereoisomerism
-
Thyroid Neoplasms / diagnostic imaging
-
Thyroid Neoplasms / metabolism
Substances
-
1-(3-iodophenyl)-3-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo(e)(1,4)diazepin-3-yl)urea
-
Iodine Radioisotopes
-
Ligands
-
Phenylurea Compounds
-
Radiopharmaceuticals
-
Receptor, Cholecystokinin A
-
Receptor, Cholecystokinin B
-
Benzodiazepines
-
Calcium